Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience
| Autor: | Barbara Melotti, F. Pannuti, Andrea Martoni, M. G. Morritti, M. Guaraldi |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Leucovorin Gastroenterology Folinic acid Bleomycin Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Cisplatin Aged 80 and over Chemotherapy business.industry Remission Induction Hematology Middle Aged Chemotherapy regimen Surgery Radiation therapy Regimen Oncology Italy Fluorouracil Head and Neck Neoplasms Toxicity Carcinoma Squamous Cell Drug Evaluation Female business medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 4 |
| ISSN: | 0923-7534 |
| Popis: | Summary Background The principal aim of our policy in the cytotoxic treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) is to reduce toxicity, to maintain or increase the response rate and consequently to improve the quality of life for these patients. In locally advanced disease the aim is to reduce the volume of the tumor and to treat micrometastases in order to achieve a better outcome of the subsequent local treatment (i.e., surgery and/or radiotherapy). In these patients the aim is to prolong survival. Patients and methods We have employed 3 different multidrug regimens with 5-FU+FA combination in 87 consecutive patients with SCCHN. Two regimens (B1, C) have been used for recurrent and/or metastatic disease and only one (B2) for previously untreated patients with locally advanced SCCHN. Regimen Bl: cisplatin (P) 30 mg/m2 i.v., 5-fluorouracil (5-FU) 500 mg/m2 i.v., folinic acid racemic form (d, 1-FA) 200 mg/m2 i.v., bleomycin (B) 15 mg im 1st and 2nd day; Regimen C: P 60 mg/m2 1st day, 5-FU 500–750 mg/m2 continuous infusion, FA 50 mg po every 4 hours, B 15 mg im 2nd and 3rd day; Regimen B2 is similar to the B1 but lasts 3 consecutive days (instead of 2) and for every 3 weeks (instead of 4). It consists of 3 cycles before surgical treatment or radiotherapy. Results There are no statistical differences in the Objective Response (OR) for the regimens B1 (39%) and C (34%). Grade 3–4 toxicity is higher in regimen B1 (50%) than in regimen C (≤8%). Conclusions Regimen C is less toxic regimen B1 with no significant difference in the OR. The primary treatment study is still ongoing but the preliminary results are promising: the remission rate is 92% (22/24,1CR + 21 PR) and the median survival is 18 months (range 3–38+). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|